Changes in use and outcomes after fibrinogen concentrate insurance coverage for critical obstetrical hemorrhage: a nationwide questionnaire survey in Japan

• Published in: Scientific reports 2024-03, Vol.14 (1), p.6711-6711, Article 6711
• Main Authors: Nii, Masafumi, Oda, Tomoaki, Morikawa, Mamoru, Nakabayashi, Yasushi, Adachi, Tomoko, Kobayashi, Takao, Itakura, Atsuo
• Format: Article
• Language: English
• Subjects: 692/308; 692/699; Allergies; Critical obstetrical hemorrhage; Edema; Embolization; Erythrocytes; Female; Fibrinogen; Fibrinogen - therapeutic use; Fibrinogen concentrates; Hemorrhage; Hemorrhage - therapy; Hemostatics; Humanities and Social Sciences; Humans; Hysterectomy; Insurance coverage; Japan - epidemiology; multidisciplinary; Polls & surveys; Public medical insurance coverage; Pulmonary Edema; Red blood cell concentrate; Science; Science (multidisciplinary); Surveys; Surveys and Questionnaires; Thromboembolism; Transfusion; Transfusion-induced allergy
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-57244-2

Fibrinogen concentrate (FC) for acquired hypofibrinogenemia associated with critical obstetrical hemorrhage (COH) was covered by public medical insurance in September 2021 in Japan. We aimed to investigate changes in the policy of FC use and its effect on COH after insurance coverage. A primary survey covering September 2020 to August 2021 and a secondary survey covering September 2021 to August 2022 were conducted at 428 higher-level medical facilities. We investigated the policy of FC use in transfusion strategy and the maternal outcomes in COH. Among the hospitals that responded to both surveys, the number of facilities that use FC increased from 51.5 (101/196) to 78.6% (154/196) ( P